Vigeo Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
86a Sherman St, Cambridge, Massachusetts...Phone Number
(617) 340-6073Website
www.vigeotherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Vigeo Therapeutics
Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. Single-agent VT1021 has been investigated in a Phase 1/2 clinical trial in patients with glioblastoma, pancreatic cancer and other solid tumors, and is currently progressing to late-stage clinical development.Explore more
Popular SearchesVigeo Therapeutics IncVigeo TherapeuticsVigeo IncVigeo LLCVigeotherapeuticsSIC Code 28,283NAICS Code 32,325Show moreVigeo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vigeo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Vigeo Therapeutics has new funding data
Check if Vigeo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Vigeo Therapeutics launches new products
Click to see if Vigeo Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Vigeo Therapeutics recently announced quarterly report
Vigeo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Vigeo Therapeutics
Check out if Vigeo Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Vigeo Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Vigeo Therapeutics
Compare insights from companies similar to Vigeo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vigeo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vigeo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vigeo Therapeutics.
Vigeo Therapeutics Tech Stack
A closer look at the technologies used by Vigeo Therapeutics
Vigeo Therapeutics News & Media
Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session
CAMBRIDGE, Mass., June 2, 2023 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma...Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients
CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent...Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
LARKSPUR, Calif.--(BUSINESS WIRE)-- #GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptiveVigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will advance into a Phase 2-3 registrational study through the company's collaboration with the Global...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vigeo Therapeutics
Sign Up For FreeTo access detailed company insights
Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. Single-agent VT1021 has been in... Read More
